BioElectronics Corporation (OTC: BIEL), a developer of medical technology products, released a Chairman's update on June 30, 2026, highlighting sales growth, cost control, and strategic progress. The company reported a small profit for calendar year 2025, driven by disciplined cost control measures including office relocation and staff reductions.
Chairman Richard Staelin, PhD, outlined several revenue-generating initiatives. The company has launched targeted advertising campaigns directed at medical professionals and healthcare providers to expand clinical awareness of its RecoveryRx product among surgeons, pain specialists, and other professionals seeking non-opioid pain management options. Additionally, consumer-focused social media advertising targeting Generation X consumers aims to increase brand visibility for drug-free solutions for chronic musculoskeletal pain.
The company continues outreach to physician-owned ambulatory surgical centers and orthopedic practices to identify a clinical trial partner for RecoveryRx. The objective is to participate in a postoperative clinical study that may support future qualification for reimbursement under the federal NO PAIN Act initiative. Staelin noted that this represents a meaningful long-term opportunity and may support broader adoption of non-opioid pain management technologies in surgical settings.
Internationally, BioElectronics is working with legal counsel in Singapore and funders in China regarding arbitration proceedings involving a former distributor that the company believes breached contractual obligations. The company remains committed to protecting its intellectual property and shareholder interests.
A key development is the strategic distribution and licensing relationship with Electrome Corporation. Initial conditions of the supply agreement have been satisfied, and BioElectronics has received Electrome's initial purchase order. Manufacturing is underway, and Electrome is planning a commercial launch of BioElectronics' pulsed shortwave therapy products through its platform. This milestone provides another pathway to increase consumer awareness and access to the company's FDA-cleared, drug-free pain therapy products.
The net effect of these efforts is an increase in monthly sales in both the OTC and professional markets. Staelin emphasized that while the Electrome relationship is meaningful, it is part of a broader strategy encompassing clinical market development, professional outreach, consumer education, international opportunities, and protection of contractual and intellectual property rights.
Despite challenges faced by emerging medical technology companies, BioElectronics is encouraged by growing interest in non-drug pain management solutions. The company believes it is well positioned within the evolving electroceutical and non-opioid pain management markets and intends to continue advancing initiatives that support sustainable growth.
